RESUMEN
Background: Stature or body height is one of the most important and useful anthropometric parameters which determines the physical identity of an individual. Cranium encompasses hard tissue components with approximately immortal behavior, reason being cranial measurements were selected for the present study for estimation of stature. Objective: This investigation aimed to assess the stature of unknown using cephalometric parameters by creating equations through regression analysis. Materials and Methods: We selected 361 dental students for the present research; among them, 210 were females and 151 were males in the age range of 21-32 years. Stature and cephalic parameters, i.e., fronto-occipital circumference, head length, and head breadth were measured for each contributor following standard methods and techniques. Cephalic Index was calculated by using the formula: Cephalic Index (CI) = (Head width/Head length) ×100. Karl Pearson's correlation coefficient of stature with cephalic parameters was calculated, and regression analysis was done to generate the formulae for stature estimation. Results: Results indicated that all cephalic measurements have strong correlation with stature, and among them, circumference of head was found to be the most reliable predictor. Conclusion: Stature of unknown or deceased can be identified using cephalic parameters as an auxiliary practice.
RESUMEN
This viewpoint was developed to revisit the burden and risks associated with postpartum depression (PPD) among incarcerated women based on a thematic review of the literature. Around one third of incarcerated pregnant women have symptoms of moderate to severe depression perinatally. In particular, PPD negatively impacts the well-being of parents and their children. Mitigating the consequences of PPD through screening, promotion of protective factors, and early identification coupled with treatment may have a substantial impact on the overall well-being of the affected children and postpartum individuals. Important risk factors for PPD in correctional populations include previous mental illness diagnosis, a lack of social support, poor pre- and perinatal care, inability to breastfeed, a lack of skin-to-skin contact, and partner violence. We recommend that correctional facilities promote the development of on-site mother-baby units and streamline the visitation process for newborns to visit parents. Improved access to pre- and postnatal care, education, and doula support is highly recommended, as well as consideration of community-based alternatives to incarceration, particularly in correctional settings with underserved mental health care needs. Future studies are needed to estimate the burden of PPD in correctional settings, identify system-related risk factors, and implement evidence-based guidelines for PPD and associated psychosocial sequelae.
Asunto(s)
Depresión Posparto , Recién Nacido , Niño , Embarazo , Femenino , Humanos , Depresión Posparto/epidemiología , Depresión Posparto/psicología , Madres/psicología , Factores de Riesgo , Violencia , Medición de RiesgoRESUMEN
Clinician-rated symptom scales are the current standard for outcome measures in Schizophrenia Spectrum Disorders (SSD) research. There has been growing interest in the development of self-report measures for people with SSD to support measurement-based care and inclusive research. We developed the Inspire Self Report Scale (ISRS), which measures the current magnitude of well-being, mood symptoms, psychosis, negative symptoms and cognition using 10 questions on a Likert or Visual analogue scale (VAS). The main aim of this report was to investigate the correlation and concordance between patient self-report and clinician ratings on the ISRS during a clinical encounter. When ratings were discordant, we sought to identify whether the participant's or psychiatrist's rating was more accurate. The results indicated a moderately strong statistically significant correlation between participant and clinician ratings. There was a moderate concordance between participant and clinician ratings on the ISRS. When the results were discordant, the participant ratings were assessed to be more accurate than the clinician rating over 70% of the time. The ISRS has distinct utility compared to existing scales due to the measurement of present symptom severity, capturing multiple clinical domains, and time efficiency and ease of use. Thus, it may be useful in clinical and research settings.
Asunto(s)
Trastornos Psicóticos , Esquizofrenia , Humanos , Esquizofrenia/diagnóstico , Autoinforme , Estudios de Factibilidad , Trastornos Psicóticos/diagnóstico , Afecto , Escalas de Valoración PsiquiátricaRESUMEN
OBJECTIVES: The objective of this study was to compare initiation of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) vs insulin glargine U100 (iGlar) along with gliclazide, exclusively in people of South Asian origin with type 2 diabetes (T2D). METHODS: The Variability of glucose Assessed in a Randomized trial comparing the Initiation of A Treatment approach with biosimilar basal Insulin analog Or a titratable iGlarLixi combinatioN in type 2 diabetes among South Asian participants (VARIATION 2 SA) trial (ClinicalTrials.gov identifier: NCT03819790) randomized insulin-naïve adults with T2D having glycated hemoglobin (A1C) 7.1% to 11% to initiate either iGlarLixi or iGlar + gliclazide. Insulin doses were titrated similarly to a prebreakfast glucose target of 4.0 to 5.5 mmol/L. Average time in range (TIR) on a masked continuous glucose monitor (CGM), A1C, fasting plasma glucose (FPG) and weight were assessed at the end of the 12-week treatment period. RESULTS: Mean baseline characteristics for the 104 randomized participants were similar between treatment groups, including the following: age, 59±11 years; diabetes duration, 13.7±7.3 years; and A1C, 8.5%±1.2%. Coprimary outcomes of average TIRs within 24- and 12-h (6 am to 6 pm) periods at the end of trial were 70.5%±16.8% and 72.9%±17.6% for iGlarLixi, whereas these TIRs were 65.6%±21.6% and 67.3%±20.7% for the iGlar + gliclazide regimen, respectively, with no significant differences between groups (p=0.35 for 24-h TIR and p=0.14 for 12-h TIR). No significant difference in secondary outcomes was observed between treatment groups. Self-reported hypoglycemic events throughout the trial period and CGM-reported hypoglycemia (<4 and <3 mmol/L) were similar between randomized treatments. CONCLUSIONS: Initiation of iGlarLixi resulted in similar TIR, A1C, FPG, weight and hypoglycemia compared with the more affordable option of starting iGlar + gliclazide in adults of South Asian origin with T2D.
Asunto(s)
Biosimilares Farmacéuticos , Diabetes Mellitus Tipo 2 , Gliclazida , Hipoglucemia , Adulto , Anciano , Biosimilares Farmacéuticos/uso terapéutico , Glucemia , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Combinación de Medicamentos , Gliclazida/uso terapéutico , Hemoglobina Glucada , Humanos , Hipoglucemia/inducido químicamente , Hipoglucemia/tratamiento farmacológico , Hipoglucemia/prevención & control , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Insulina Glargina/uso terapéutico , Persona de Mediana EdadRESUMEN
Background: Industrial workers are exposed to dust and pollutants and thus they get occupational disorders when exposed for a long duration. Occupational diseases mainly affect the respiratory system more than other systems. Some of the respiratory occupation disorders are asbestosis, silicosis, coal worker's pneumoconiosis, work-related asthma, and so on, as the duration of exposure of pollutants increases the pulmonary function decreases. Method: A total of 100 subjects working in the Brick factories near Wardha district, Maharashtra were examined using a portable spirometer. Their pulmonary function test was assessed three times and the best out of three values was taken. A pretested questionnaire was filled out by the workers which consisted of their sociodemographic details. Consent was obtained from all the subjects for this in their native language. Similarly, a pretested questionnaire was filled by 50 subjects among the normal population, that is, those not working in brick factories, and consent was obtained from all. And then, their pulmonary function test was carried out using a portable spirometer and the best out of the three values was taken. Statistical analysis was done by using descriptive and inferential statistics using the software. Results: As analyzed by the pulmonary function test data values collected among the brick factory workers and the control group, there was a significant decrease seen in the values of the pulmonary function test of brick factory workers. And as analyzed by the pulmonary function test values of smokers and non-smokers among the brick factory workers, it was seen that there was a significant P value of 0.0001, thus a decrease in pulmonary function test among smokers. Conclusion: In this study, we evaluate the respiratory function test among the brick factory workers and the control group and make the workers aware of the damage their habits have on their lung capacity and function based on the evaluation of the predicted and the actual value and thus helps them lead a better life. In this study, we also compare the values of pulmonary function tests among the brick factory workers and control groups.
RESUMEN
BACKGROUND: Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. OBJECTIVES: This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. METHODS: Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. RESULTS: Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10-7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. LIMITATIONS: The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. CONCLUSION: The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121.
Asunto(s)
Buprenorfina , Trastornos Relacionados con Opioides , Buprenorfina/uso terapéutico , Proteínas Quinasas Dependientes de Calcio-Calmodulina/uso terapéutico , Proteínas del Ojo/uso terapéutico , Estudio de Asociación del Genoma Completo , Humanos , Metadona/uso terapéutico , Tratamiento de Sustitución de Opiáceos , Trastornos Relacionados con Opioides/tratamiento farmacológico , Trastornos Relacionados con Opioides/genética , Polimorfismo de Nucleótido Simple/genéticaRESUMEN
BACKGROUND: The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance. METHODS: The databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible. DISCUSSION: This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes. SYSTEMATIC REVIEW REGISTRATION: This systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration ID CRD42020169121).
Asunto(s)
Analgésicos Opioides , Estudio de Asociación del Genoma Completo , Trastornos Relacionados con Opioides , Analgésicos Opioides/uso terapéutico , Humanos , Metaanálisis como Asunto , América del Norte , Trastornos Relacionados con Opioides/tratamiento farmacológico , Trastornos Relacionados con Opioides/genética , Revisiones Sistemáticas como Asunto , Resultado del TratamientoRESUMEN
INTRODUCTION: A brain tumor occurs when neurons are mutated and thus abnormal cells are formed. Glioma and meningioma are the two most common types, comprising approximately 75% of all brain tumors. The incidence rate of all primary brain tumors was 15.80/100,000 person-years in females and 14.33/100,000 person-years in males. An association of higher risk of brain tumors in adults with cured meat and fruit/vegetable consumption, the primary source of dietary N-nitroso compounds, is seen. Cigarette smoking is a major source of chemical carcinogens. The present study aimed at determining the effects of lifestyle and dietary habits in the development of brain tumor. METHODS: The study aimed at the assessment of various dietary factors, lifestyle, and occupational and personal habits in patients diagnosed with brain tumor in a rural tertiary health-care hospital, using a structured questionnaire and statistical analysis. RESULTS: It was observed that - (1) people with stressful, sedentary lifestyle and wrong diet and those addicted to alcohol consumption and the habit of cigarette smoking have higher risk of brain tumors; (2) males are more prone to brain tumors; and (3) among subtypes, majority had glioblastoma and the least had meningioma and opdivoglioblastoma and according to location, majority had cerebellopontine angle tumor and the least had left thalamic glioma and multicentric glioma. Primary care to preoperative brain tumor patients should be given in terms of preventing exposure to radiations, avoiding cigarette smoking, providing healthy diet, and avoiding chronic stress and environmental pollution and postoperative patients should be taken care including avoiding infections by maintaining proper hygiene and providing healthy diet for their speedy recovery. CONCLUSION: People with stressful life condition, wrong diet, and sedentary lifestyle and those addicted to alcohol, with the habit of cigarette smoking, have higher risk of brain tumors. Males are more prone to brain tumors.